Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

Factors influencing decline in quality of life in smokers without airflow obstruction: The COPDGene study.

Parekh TM, Bhatia S, Cherrington A, Kim YI, Lambert A, Iyer A, Regan EA, DeMeo DL, Han M, Dransfield MT.

Respir Med. 2019 Nov 15;161:105820. doi: 10.1016/j.rmed.2019.105820. [Epub ahead of print]

PMID:
31759270
2.

COPDGene® 2019: Redefining the Diagnosis of Chronic Obstructive Pulmonary Disease.

Lowe KE, Regan EA, Anzueto A, Austin E, Austin JHM, Beaty TH, Benos PV, Benway CJ, Bhatt SP, Bleecker ER, Bodduluri S, Bon J, Boriek AM, Boueiz AR, Bowler RP, Budoff M, Casaburi R, Castaldi PJ, Charbonnier JP, Cho MH, Comellas A, Conrad D, Costa Davis C, Criner GJ, Curran-Everett D, Curtis JL, DeMeo DL, Diaz AA, Dransfield MT, Dy JG, Fawzy A, Fleming M, Flenaugh EL, Foreman MG, Fortis S, Gebrekristos H, Grant S, Grenier PA, Gu T, Gupta A, Han MK, Hanania NA, Hansel NN, Hayden LP, Hersh CP, Hobbs BD, Hoffman EA, Hogg JC, Hokanson JE, Hoth KF, Hsiao A, Humphries S, Jacobs K, Jacobson FL, Kazerooni EA, Kim V, Kim WJ, Kinney GL, Koegler H, Lutz SM, Lynch DA, MacIntye NR Jr, Make BJ, Marchetti N, Martinez FJ, Maselli DJ, Mathews AM, McCormack MC, McDonald MN, McEvoy CE, Moll M, Molye SS, Murray S, Nath H, Newell JD Jr, Occhipinti M, Paoletti M, Parekh T, Pistolesi M, Pratte KA, Putcha N, Ragland M, Reinhardt JM, Rennard SI, Rosiello RA, Ross JC, Rossiter HB, Ruczinski I, San Jose Estepar R, Sciurba FC, Sieren JC, Singh H, Soler X, Steiner RM, Strand MJ, Stringer WW, Tal-Singer R, Thomashow B, Vegas Sánchez-Ferrero G, Walsh JW, Wan ES, Washko GR, Michael Wells J, Wendt CH, Westney G, Wilson A, Wise RA, Yen A, Young K, Yun J, Silverman EK, Crapo JD.

Chronic Obstr Pulm Dis. 2019 Nov;6(5):384-399. doi: 10.15326/jcopdf.6.5.2019.0149.

3.

Marijuana Use Among Young Adults (18-44 Years of Age) and Risk of Stroke: A Behavioral Risk Factor Surveillance System Survey Analysis.

Parekh T, Pemmasani S, Desai R.

Stroke. 2019 Nov 11:STROKEAHA119027828. doi: 10.1161/STROKEAHA.119.027828. [Epub ahead of print]

PMID:
31707926
4.

Psychiatric disorders in the U.S. transgender population.

Hanna B, Desai R, Parekh T, Guirguis E, Kumar G, Sachdeva R.

Ann Epidemiol. 2019 Nov;39:1-7.e1. doi: 10.1016/j.annepidem.2019.09.009. Epub 2019 Oct 4.

PMID:
31679894
5.

ApoE4 Alters ABCA1 Membrane Trafficking in Astrocytes.

Rawat V, Wang S, Sima J, Bar R, Liraz O, Gundimeda U, Parekh T, Chan J, Johansson JO, Tang C, Chui HC, Harrington MG, Michaelson DM, Yassine HN.

J Neurosci. 2019 Nov 27;39(48):9611-9622. doi: 10.1523/JNEUROSCI.1400-19.2019. Epub 2019 Oct 22.

PMID:
31641056
6.

Reply to: Regional variation in cardiac arrest for patients with sepsis.

Desai R, Parekh T, Hanna B, Sachdeva R, Kumar G.

Resuscitation. 2019 Nov;144:211-212. doi: 10.1016/j.resuscitation.2019.09.018. Epub 2019 Sep 23. No abstract available.

PMID:
31557517
7.

Macular hole following phakic intraocular lens implantation and its management.

Kumar A, Padhy SK, Dhiman R, Kumar P, Parekh T, Varshney T.

Indian J Ophthalmol. 2019 Oct;67(10):1758-1760. doi: 10.4103/ijo.IJO_126_19.

8.

Regional trends in In-hospital Cardiac Arrest following sepsis-related admissions and subsequent mortality.

Desai R, Parekh T, Patel U, Hanna B, Damarlapally N, Patel C, Doshi R, Savani S, Sachdeva R, Kumar G.

Resuscitation. 2019 Oct;143:35-41. doi: 10.1016/j.resuscitation.2019.08.007. Epub 2019 Aug 10.

PMID:
31408680
9.

Adherence to Pulmonary Rehabilitation in COPD: A QUALITATIVE EXPLORATION OF PATIENT PERSPECTIVES ON BARRIERS AND FACILITATORS.

Oates GR, Niranjan SJ, Ott C, Scarinci IC, Schumann C, Parekh T, Dransfield MT.

J Cardiopulm Rehabil Prev. 2019 Sep;39(5):344-349. doi: 10.1097/HCR.0000000000000436.

PMID:
31348127
10.

Application of the community health worker model in adult asthma and COPD in the U.S.: a systematic review.

Parekh TM, Copeland CR, Dransfield MT, Cherrington A.

BMC Pulm Med. 2019 Jun 26;19(1):116. doi: 10.1186/s12890-019-0878-7.

11.

Epidemiology of acute coronary syndrome co-existent with allergic/hypersensitivity/anaphylactic reactions (Kounis syndrome) in the United States: A nationwide inpatient analysis.

Desai R, Parekh T, Patel U, Fong HK, Samani S, Patel C, Savani S, Doshi R, Kumar G, Sachdeva R.

Int J Cardiol. 2019 Oct 1;292:35-38. doi: 10.1016/j.ijcard.2019.06.002. Epub 2019 Jun 8.

PMID:
31204069
12.

Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma.

Patel S, von Mehren M, Reed DR, Kaiser P, Charlson J, Ryan CW, Rushing D, Livingston M, Singh A, Seth R, Forscher C, D'Amato G, Chawla SP, McCarthy S, Wang G, Parekh T, Knoblauch R, Hensley ML, Maki RG, Demetri GD.

Cancer. 2019 Aug 1;125(15):2610-2620. doi: 10.1002/cncr.32117. Epub 2019 Jun 7.

13.

Impact of gout on in-hospital outcomes of acute coronary syndrome-related hospitalizations and revascularizations: Insights from the national inpatient sample.

Desai R, Parekh T, Goyal H, Fong HK, Zalavadia D, Damarlapally N, Doshi R, Savani S, Kumar G, Sachdeva R.

World J Cardiol. 2019 May 26;11(5):137-148. doi: 10.4330/wjc.v11.i5.137.

14.

Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors.

Bahleda R, Italiano A, Hierro C, Mita A, Cervantes A, Chan N, Awad M, Calvo E, Moreno V, Govindan R, Spira A, Gonzalez M, Zhong B, Santiago-Walker A, Poggesi I, Parekh T, Xie H, Infante J, Tabernero J.

Clin Cancer Res. 2019 Aug 15;25(16):4888-4897. doi: 10.1158/1078-0432.CCR-18-3334. Epub 2019 May 14.

PMID:
31088831
15.

Determinants of cigarette smoking status in a national cohort of black and white adult ever smokers in the USA: a cross-sectional analysis of the REGARDS study.

Parekh TM, Wu C, McClure LA, Howard VJ, Cushman M, Malek AM, Harrington KF, Cherrington AL, Dransfield MT, Bhatia S.

BMJ Open. 2019 May 10;9(5):e027175. doi: 10.1136/bmjopen-2018-027175.

16.

Low-Density Lipoprotein Particle Size Subfractions and Cerebral Amyloidosis.

Lee S, Parekh T, King SM, Reed B, Chui HC, Krauss RM, Yassine HN.

J Alzheimers Dis. 2019;68(3):983-990. doi: 10.3233/JAD-181252.

PMID:
30883362
17.

Alarming Increasing Trends in Hospitalizations and Mortality With Heyde's Syndrome: A Nationwide Inpatient Perspective (2007 to 2014).

Desai R, Parekh T, Singh S, Patel U, Fong HK, Zalavadia D, Savani S, Doshi R, Sachdeva R, Kumar G.

Am J Cardiol. 2019 Apr 1;123(7):1149-1155. doi: 10.1016/j.amjcard.2018.12.043. Epub 2019 Jan 7.

PMID:
30660352
18.

Efficacy and tolerability of trabectedin in elderly patients with sarcoma: subgroup analysis from a phase III, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma.

Jones RL, Demetri GD, Schuetze SM, Milhem M, Elias A, Van Tine BA, Hamm J, McCarthy S, Wang G, Parekh T, Knoblauch R, Hensley ML, Maki RG, Patel S, von Mehren M.

Ann Oncol. 2018 Sep 1;29(9):1995-2002. doi: 10.1093/annonc/mdy253.

19.

Implications of DRG Classification in a Bundled Payment Initiative for COPD.

Parekh TM, Bhatt SP, Westfall AO, Wells JM, Kirkpatrick D, Iyer AS, Mugavero M, Willig JH, Dransfield MT.

Am J Accountable Care. 2017 Dec;5(4):12-18. Epub 2017 Dec 8.

20.

Hepatic safety analysis of trabectedin: results of a pharmacokinetic study with trabectedin in patients with hepatic impairment and experience from a phase 3 clinical trial.

Calvo E, Azaro A, Rodon J, Dirix L, Huizing M, Senecal FM, LoRusso P, Yee L, Poggesi I, de Jong J, Triantos S, Park YC, Knoblauch RE, Parekh TV, Demetri GD, von Mehren M.

Invest New Drugs. 2018 Jun;36(3):476-486. doi: 10.1007/s10637-017-0546-9. Epub 2017 Nov 27.

PMID:
29177975
21.

Spontaneous resolution of symptomatic lumbar synovial cyst.

Sinha P, Panbehchi S, Lee MT, Parekh T, Pal D.

J Surg Case Rep. 2016 Oct 31;2016(10):rjw166. doi: 10.1093/jscr/rjw166. eCollection 2016 Oct.

22.

Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial.

Hensley ML, Patel SR, von Mehren M, Ganjoo K, Jones RL, Staddon A, Rushing D, Milhem M, Monk B, Wang G, McCarthy S, Knoblauch RE, Parekh TV, Maki RG, Demetri GD.

Gynecol Oncol. 2017 Sep;146(3):531-537. doi: 10.1016/j.ygyno.2017.06.018. Epub 2017 Jun 24.

23.

Results of a Medicare Bundled Payments for Care Improvement Initiative for Chronic Obstructive Pulmonary Disease Readmissions.

Bhatt SP, Wells JM, Iyer AS, Kirkpatrick DP, Parekh TM, Leach LT, Anderson EM, Sanders JG, Nichols JK, Blackburn CC, Dransfield MT.

Ann Am Thorac Soc. 2017 May;14(5):643-648. doi: 10.1513/AnnalsATS.201610-775BC.

24.

Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma.

Orlowski RZ, Nagler A, Sonneveld P, Bladé J, Hajek R, Spencer A, Robak T, Dmoszynska A, Horvath N, Spicka I, Sutherland HJ, Suvorov AN, Xiu L, Cakana A, Parekh T, San-Miguel JF.

Cancer. 2016 Jul 1;122(13):2050-6. doi: 10.1002/cncr.30026. Epub 2016 May 18.

25.

A case of peripheral T-cell lymphoma, not otherwise specified in a HCV and HTLV-II-positive patient, diagnosed by abdominal fluid cytology.

Ameri MD, Parekh TM, Qian YW, Elghetany MT, Schnadig V, Nawgiri R.

J Gastrointest Oncol. 2016 Apr;7(Suppl 1):S96-9. doi: 10.3978/j.issn.2078-6891.2015.054.

26.

Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.

Demetri GD, von Mehren M, Jones RL, Hensley ML, Schuetze SM, Staddon A, Milhem M, Elias A, Ganjoo K, Tawbi H, Van Tine BA, Spira A, Dean A, Khokhar NZ, Park YC, Knoblauch RE, Parekh TV, Maki RG, Patel SR.

J Clin Oncol. 2016 Mar 10;34(8):786-93. doi: 10.1200/JCO.2015.62.4734. Epub 2015 Sep 14.

27.

Radiological and Pathological Predictors of Response to Neoadjuvant Chemotherapy in Breast Cancer: A Brief Literature Review.

Parekh T, Dodwell D, Sharma N, Shaaban AM.

Pathobiology. 2015 Sep;82(3-4):124-32. doi: 10.1159/000433582. Epub 2015 Aug 31. Review.

28.

Phase I study of the safety and pharmacokinetics of trabectedin with docetaxel in patients with advanced malignancies.

von Mehren M, Bookman M, Meropol NJ, Weiner LM, Sherman E, Li J, Knoblauch R, Parekh T, Cohen RB.

Cancer Chemother Pharmacol. 2015 May;75(5):1047-55. doi: 10.1007/s00280-015-2705-z. Epub 2015 Mar 20.

29.

Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study.

Monk BJ, Ghatage P, Parekh T, Henitz E, Knoblauch R, Matos-Pita AS, Nieto A, Park YC, Cheng PS, Li W, Favis R, Ricci D, Poveda A.

Ann Oncol. 2015 May;26(5):914-20. doi: 10.1093/annonc/mdv071. Epub 2015 Feb 26.

PMID:
25722380
30.

Atypical teratoid rhabdoid tumour of the spine: report of a case and literature review.

Sinha P, Ahmad M, Varghese A, Parekh T, Ismail A, Chakrabarty A, Tyagi A, Chumas P.

Eur Spine J. 2015 May;24 Suppl 4:S472-84. doi: 10.1007/s00586-014-3445-1. Epub 2014 Nov 6. Review.

PMID:
25374299
31.

Hypoglycemia after antimicrobial drug prescription for older patients using sulfonylureas.

Parekh TM, Raji M, Lin YL, Tan A, Kuo YF, Goodwin JS.

JAMA Intern Med. 2014 Oct;174(10):1605-12. doi: 10.1001/jamainternmed.2014.3293.

32.

Impact of cytochrome P450 3A4 inducer and inhibitor on the pharmacokinetics of trabectedin in patients with advanced malignancies: open-label, multicenter studies.

Machiels JP, Staddon A, Herremans C, Keung C, Bernard A, Phelps C, Khokhar NZ, Knoblauch R, Parekh TV, Dirix L, Sharma S.

Cancer Chemother Pharmacol. 2014 Oct;74(4):729-37. doi: 10.1007/s00280-014-2554-1. Epub 2014 Aug 7.

PMID:
25100135
33.

The association between body composition and toxicities from the combination of Doxil and trabectedin in patients with advanced relapsed ovarian cancer.

Prado CM, Baracos VE, Xiao J, Birdsell L, Stuyckens K, Park YC, Parekh T, Sawyer MB.

Appl Physiol Nutr Metab. 2014 Jun;39(6):693-8. doi: 10.1139/apnm-2013-0403. Epub 2014 Jan 23.

PMID:
24869973
34.

Predictors of early readmission among patients 40 to 64 years of age hospitalized for chronic obstructive pulmonary disease.

Sharif R, Parekh TM, Pierson KS, Kuo YF, Sharma G.

Ann Am Thorac Soc. 2014 Jun;11(5):685-94. doi: 10.1513/AnnalsATS.201310-358OC.

35.

Nibrin is a marker of clinical outcome in patients with advanced serous ovarian cancer treated in the phase III OVA-301 trial.

Monk BJ, Kaye SB, Poveda A, Herzog TJ, Aracil M, Nieto A, Badri N, Parekh TV, Tanović A, Galmarini CM.

Gynecol Oncol. 2014 Jan;132(1):176-80. doi: 10.1016/j.ygyno.2013.10.032. Epub 2013 Nov 5.

PMID:
24211400
36.

Value of isolated IgA anti-β2 -glycoprotein I positivity in the diagnosis of the antiphospholipid syndrome.

Murthy V, Willis R, Romay-Penabad Z, Ruiz-Limón P, Martínez-Martínez LA, Jatwani S, Jajoria P, Seif A, Alarcón GS, Papalardo E, Liu J, Vilá LM, McGwin G Jr, McNearney TA, Maganti R, Sunkureddi P, Parekh T, Tarantino M, Akhter E, Fang H, Gonzalez EB, Binder WR, Norman GL, Shums Z, Teodorescu M, Reveille JD, Petri M, Pierangeli SS.

Arthritis Rheum. 2013 Dec;65(12):3186-93. doi: 10.1002/art.38131.

37.

Intramedullary abscess of the upper cervical spinal cord. Unusual presentation and dilemmas of management: case report.

Sinha P, Parekh T, Pal D.

Clin Neurol Neurosurg. 2013 Sep;115(9):1845-50. doi: 10.1016/j.clineuro.2013.01.008. Epub 2013 Feb 26. No abstract available.

PMID:
23453154
38.

Trabectedin as single agent in relapsed advanced ovarian cancer: results from a retrospective pooled analysis of three phase II trials.

del Campo JM, Sessa C, Krasner CN, Vermorken JB, Colombo N, Kaye S, Gore M, Zintl P, Gómez J, Parekh T, Park YC, McMeekin S.

Med Oncol. 2013 Mar;30(1):435. doi: 10.1007/s12032-012-0435-1. Epub 2013 Feb 9.

PMID:
23397080
39.

Patient-reported outcomes in relapsed ovarian cancer: results from a randomized Phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD alone.

Krasner CN, Poveda A, Herzog TJ, Vermorken JB, Kaye SB, Nieto A, Claret PL, Park YC, Parekh T, Monk BJ.

Gynecol Oncol. 2012 Oct;127(1):161-7. doi: 10.1016/j.ygyno.2012.06.034. Epub 2012 Jul 2.

PMID:
22765965
40.

Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis.

Monk BJ, Herzog TJ, Kaye SB, Krasner CN, Vermorken JB, Muggia FM, Pujade-Lauraine E, Park YC, Parekh TV, Poveda AM.

Eur J Cancer. 2012 Oct;48(15):2361-8. doi: 10.1016/j.ejca.2012.04.001. Epub 2012 Apr 26.

PMID:
22541893
42.

Effect of trabectedin on the QT interval in patients with advanced solid tumor malignancies.

Thertulien R, Manikhas GM, Dirix LY, Vermorken JB, Park K, Jain MM, Jiao JJ, Natarajan J, Parekh T, Zannikos P, Staddon AP.

Cancer Chemother Pharmacol. 2012 Feb;69(2):341-50. doi: 10.1007/s00280-011-1697-6. Epub 2011 Jul 8.

43.

Circulating tumor cells predict progression free survival and overall survival in patients with relapsed/recurrent advanced ovarian cancer.

Poveda A, Kaye SB, McCormack R, Wang S, Parekh T, Ricci D, Lebedinsky CA, Tercero JC, Zintl P, Monk BJ.

Gynecol Oncol. 2011 Sep;122(3):567-72. doi: 10.1016/j.ygyno.2011.05.028. Epub 2011 Jun 12.

PMID:
21664658
44.

Correlation between CA-125 serum level and response by RECIST in a phase III recurrent ovarian cancer study.

Herzog TJ, Vermorken JB, Pujade-Lauraine E, Provencher DM, Jagiello-Gruszfeld A, Kong B, Boman K, Park YC, Parekh T, Lebedinsky C, Gómez J, Monk BJ.

Gynecol Oncol. 2011 Aug;122(2):350-5. doi: 10.1016/j.ygyno.2011.04.005. Epub 2011 May 5.

PMID:
21546066
45.

Trabectedin has a low cardiac risk profile: a comprehensive cardiac safety analysis.

Lebedinsky C, Gómez J, Park YC, Nieto A, Soto-Matos A, Parekh T, Alfaro V, Roy E, Lardelli P, Kahatt C.

Cancer Chemother Pharmacol. 2011 Nov;68(5):1223-31. doi: 10.1007/s00280-011-1614-z. Epub 2011 Mar 18.

PMID:
21416137
46.

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval.

Kaye SB, Colombo N, Monk BJ, Tjulandin S, Kong B, Roy M, Chan S, Filipczyk-Cisarz E, Hagberg H, Vergote I, Lebedinsky C, Parekh T, Santabárbara P, Park YC, Nieto A, Poveda A.

Ann Oncol. 2011 Jan;22(1):49-58. doi: 10.1093/annonc/mdq353. Epub 2010 Jul 19.

47.

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial.

Poveda A, Vergote I, Tjulandin S, Kong B, Roy M, Chan S, Filipczyk-Cisarz E, Hagberg H, Kaye SB, Colombo N, Lebedinsky C, Parekh T, Gómez J, Park YC, Alfaro V, Monk BJ.

Ann Oncol. 2011 Jan;22(1):39-48. doi: 10.1093/annonc/mdq352. Epub 2010 Jul 19.

48.

Evaluation of various physico-chemical properties of Hibiscus sabdariffa and L. casei incorporated probiotic yoghurt.

Rasdhari M, Parekh T, Dave N, Patel V, Subhash R.

Pak J Biol Sci. 2008 Sep 1;11(17):2101-8.

PMID:
19266923
49.

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.

Orlowski RZ, Nagler A, Sonneveld P, Bladé J, Hajek R, Spencer A, San Miguel J, Robak T, Dmoszynska A, Horvath N, Spicka I, Sutherland HJ, Suvorov AN, Zhuang SH, Parekh T, Xiu L, Yuan Z, Rackoff W, Harousseau JL.

J Clin Oncol. 2007 Sep 1;25(25):3892-901. Epub 2007 Aug 6.

PMID:
17679727
50.

Transforming growth factor-beta, estrogen, and progesterone converge on the regulation of p27Kip1 in the normal and malignant endometrium.

Lecanda J, Parekh TV, Gama P, Lin K, Liarski V, Uretsky S, Mittal K, Gold LI.

Cancer Res. 2007 Feb 1;67(3):1007-18.

Supplemental Content

Loading ...
Support Center